B · Normal
On September 30, Eli Lilly announced the research data of Eloratzp (a combination therapy of Eloralintide and Tilpotide). The results showed that the combination therapy was more effective than tilpotide 15 mg monotherapy in terms of weight loss and glycated hemoglobin (A1C) reduction. Eli Lilly's amyloid peptide drug combination achieved a 23% weight loss effect in the study.
weight loss pills 🕐 2026-09-30 22:17
#weight loss pills
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

On September 30th, AbbVie announced that its drug under development, ABBV-295, s 09-30 17:52 September 23rd, Novo Nordisk is reported to be considering upgrading its New Yor 09-23 12:03 On September 21, Novo Nordisk stated that Mexico is the next market for Wegovy o 09-21 20:59 On September 21, the head of Novo Nordisk in the United States said that since J 09-21 20:19 On September 21, the CEO of Novo Nordisk stated that it would launch new innovat 09-21 16:32 On September 21, Novo Nordisk’s CEO stated that by 2030, the company’s productio 09-21 16:28

Comments

0/500
Captcha (click to refresh)
No comments yet